DexCom, Inc. vs Visa Inc — how do they compare? DexCom, Inc. trades at $89.53 (market cap $33.08B), while Visa Inc trades at $362.71 (market cap $668.96B). The key difference: Visa Inc is far larger — about 20.2× DexCom, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | V | |
|---|---|---|
Market Cap | $33.08B | $668.96B |
Sector | Health | Financials |
52-Week High | $89.53 | $370.47 |
52-Week Low | $54.84 | $295.52 |
Enterprise Value | $32.53B | $679.54B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Visa (V) trades at $361.32, down 0.33% on the day, with strong fundamentals including 50.78% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains bullish moving averages. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa for future payment system evolution. Financial trends show revenue growth from $29.3B in 2022 to $40B in 2025, with robust cash flow generation.
Visa presents a compelling long-term investment with 85% analyst buy ratings and $426.31 consensus price target suggesting 18% upside. Key risks include fintech competition and regulatory pressures, but the company's dominant market position, high profitability, and innovation in digital payments support continued growth potential.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →